Pimavanserin for Psychosis in Parkinson ’s Disease Dementia: Subgroup Analysis of the HARMONY Trial

Background: Pimavanserin is FDA-approved to treat Parkinson ’s disease (PD) psychosis. We analyzed the effect of pimavanserin on psychosis in the PD dementia (PDD) subgroup from the phase 3 HARMONY trial.

Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: D. Weintraub, A.J. Espay, V.D. Sharma, P.N. Tariot, V. Abler, S. Pathak, S. Stankovic Source Type: research